Physician profile
Roy Whitaker
NPI 1285638866
$3,759.72
in general payments reported to CMS, 2019-2025
19 companies · $782 in 2025
The $782 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $986 · 2020: $457 · 2021: $495 · 2022: $381 · 2023: $362 · 2024: $296 · 2025: $782.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,441.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,440.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $887.35 | 2019-2022 | |
| Alcon Vision LLC | $492.34 | 2022-2025 | Tryptyr, Rocklatan, Rhopressa |
| Sun Pharmaceutical Industries INC. | $392.80 | 2019-2025 | Cequa |
| Bausch & Lomb Americas INC. | $356.12 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $260.74 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $240.83 | 2019-2023 | |
| Tarsus Pharmaceuticals, INC. | $212.62 | 2024-2025 | Xdemvy |
| Aerie Pharmaceuticals, INC. | $174.77 | 2019-2021 | |
| Oyster Point Pharma, INC. | $168.47 | 2022-2024 | Tyrvaya |
| New World Medical,INC. | $132.28 | 2019 | |
| Abbvie INC. | $112.51 | 2022-2024 | Alphagan P, Lumigan, Vuity |
| Kala Pharmaceuticals, INC. | $94.71 | 2019-2022 | |
| Shire North American Group INC | $58.97 | 2019 | |
| Harrow Eye, LLC | $57.50 | 2023-2025 | Vevye |
| Mallinckrodt Hospital Products INC. | $33.95 | 2025 | Acthar |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ivantis, INC | $29.49 | 2021 | |
| Horizon Therapeutics Plc | $19.30 | 2023 | Tepezza |
| Akorn Operating Company LLC | $17.49 | 2021 | |
| Thea Pharma INC. | $17.48 | 2024 | Iyuzeh |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Whitaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.